BLO News

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an existing European maritime shipping customer. Under this agreement, the Company will deliver an additional BreathLogix unit to enhance operational safety among crew members through pre-access breath alcohol testing. The BreathLogix system will be integrated with the cloud-based BreathLogix Connect platform, powered by Amazon Web Services, enabling real-time alerts, centralized data management, and seamless reporting. Additionally, the device will feature facial recognition technology for rapid and secure crew member identification.

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has delivered multiple Cannabix Marijuana Breath Test (“MBT”) units to Omega Laboratories Inc. of Ohio, USA (“Omega Laboratories” or “Omega”) to initiate phased commercialization efforts. The MBT hardware includes Cannabix’s proprietary Breath Collection Unit (BCU) and Breath Cartridges (BC) technology which are designed to collect and preserve breath samples to be analysed with Omega’s Laboratory Developed Test Method to detect delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis, in breath (see Figures 1 and 2). The MBT is focused on “recent use” detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (1).

VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce William (Bill) R. Corl has joined the board of directors of the Company. Mr. Corl is the Chief Executive Officer for Omega Laboratories, Inc., (“Omega”) one of the leading advanced specimen drug testing laboratories in the world. Omega and Cannabix have been working together since May 2024 under a strategic partnership and development agreement to advance commercialization of the Company’s Marijuana Breath Test (MBT) technology.